TORNTPHARM

TORRENT PHARMACEUTICALS

Large Cap BSE: 500420 NSE: TORNTPHARM
₹1615.15
-4.75 (-0.29%)
  • Advice
  • Hold
As on 07 December, 2022 | 06:27

Torrent Pharmaceuticals Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in TORRENT PHARMACEUTICALS

Start SIP

Torrent Pharmaceuticals Share Price

Torrent Pharmaceuticals Share Returns

  • Over 1 Month -3.1%
  • Over 3 Month 7.47%
  • Over 6 Month 16.14%
  • Over 1 Year 9.99%

Torrent Pharmaceuticals Key Statistics

P/E Ratio 68.6
PEG Ratio -1.8
Market Cap Cr 54,664
Price to Book Ratio 9.2
EPS 29.1
Dividend 1.5
Relative Strength Index 46.55
Money Flow Index 51.77
MACD Signal 7.18
Average True Range 34.72

Torrent Pharmaceuticals Investment Rating

  • Master Rating:
  • Torrent Pharmaceuticals has an operating revenue of Rs. 8,877.00 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 14% is healthy, ROE of 13% is good. The company has a reasonable debt to equity of 36%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 9% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 60 which is a FAIR score but needs to improve its earnings, a RS Rating of 56 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 110 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Torrent Pharmaceuticals Financials
IndicatorSep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 1,9281,9331,6621,5881,7991,6811,443
Operating Expenses Qtr Cr 1,3081,2681,1791,1611,1821,1171,037
Operating Profit Qtr Cr 620665483427617578431
Depreciation Qtr Cr 156149147152153150152
Interest Qtr Cr 62515257646669
Tax Qtr Cr 1411671248512813822
Net Profit Qtr Cr 272327221170326274279

Torrent Pharmaceuticals Technicals

EMA & SMA

Current Price
1615.15
-4.75 (-0.29%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 1630.09
  • 50 Day
  • 1607.86
  • 100 Day
  • 1566.78
  • 200 Day
  • 1518.66
  • 20 Day
  • 1635.58
  • 50 Day
  • 1609.6
  • 100 Day
  • 1564.41
  • 200 Day
  • 1474.98

Torrent Pharmaceuticals Resistance and Support

PIVOT
₹1618.55
Resistance
First Resistance 1633.45
Second Resistance 1647
Third Resistance 1661.9
RSI 46.55
MFI 51.77
MACD Single Line 7.18
MACD 2.66
Support
First Resistance 1605
Second Resistance 1590.1
Third Resistance 1576.55

Torrent Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 114,513 5,993,610 52.34
Week 282,300 17,739,757 62.84
1 Month 249,454 14,777,675 59.24
6 Month 278,349 14,905,584 53.55

Torrent Pharmaceuticals Result Highlights

Torrent Pharmaceuticals Synopsis

NSE-Medical-Generic Drugs

Torrent Pharmac is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 6742.32 Cr. and Equity Capital is Rs. 84.62 Cr. for the Year ended 31/03/2022. Torrent Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 15/07/1972 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1972PLC002126 and registration number is 002126.
Market Cap 54,664
Sales 7,111
Shares in Float 9.81
No of funds 559
Yield 2.04
Book Value 8.62
U/D Vol ratio 1.3
LTDebt / Equity 31
Alpha 0.01
Beta 0.62

Torrent Pharmaceuticals

Owner NameSep-22Jul-22Jun-22Mar-22
Promoters 71.25%71.25%71.25%
Mutual Funds 6.72%7.72%7.78%
Insurance Companies 2.16%0.04%0.04%
Foreign Portfolio Investors 11.37%10.79%10.8%
Financial Institutions/ Banks
Individual Investors 4.59%7.13%7.1%
Others 3.91%3.07%3.03%

Torrent Pharmaceuticals Management

Name Designation
Mr. Sudhir Mehta Chairman Emeritus
Mr. Samir Mehta Executive Chairman
Mr. Shailesh Haribhakti Independent Director
Mr. Haigreve Khaitan Independent Director
Ms. Ameera Shah Independent Director
Ms. Nayantara Bali Independent Director
Dr. Maurice Chagnaud Independent Director
Mr. Jinesh Shah Director - Operations
Mr. Manish Mahendra Choksi Independent Director
Mr. Aman Samir Mehta Whole Time Director

Torrent Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Torrent Pharmaceuticals Corporate Action

Date Purpose Remarks
2022-10-21 Quarterly Results
2022-07-29 Quarterly Results
2022-05-25 Audited Results, Dividend & Bonus issue
2022-01-25 Quarterly Results & Interim Dividend
2021-10-26 Quarterly Results
Date Purpose Remarks
2022-06-06 FINAL Rs.8.00 per share(160%)Final Dividend
2022-06-06 SPECIAL Rs.15.00 per share(300%)Special Dividend
2022-02-03 INTERIM Rs.25.00 per share(500%)Interim Dividend
2021-06-18 FINAL Rs.15.00 per share(300%)Final Dividend
2021-02-16 INTERIM Rs.20.00 per share(400%)Interim Dividend
Date Purpose Remarks
2022-07-11 Bonus Rs.0.00 issue of equity shares in the ratio of 1:1 of Rs. 5/-.

Torrent Pharmaceuticals MF Shareholding

Name Amount(cr)
ICICI Prudential Balanced Advantage Fund Growth 44002
ICICI Prudential Bluechip Fund Growth 34823
Mirae Asset Large Cap Fund Regular Growth 34407
UTI Flexi Cap Fund Regular Plan Growth 26133
Mirae Asset Emerging Bluechip Fund Growth 23691

About Company

Torrent Pharmaceuticals Limited (TPL) is one of India’s leading pharmaceutical companies, with a strong presence in research and development, manufacturing and marketing. In terms of oncology specialty therapies, TPL is one of India's leading pharma companies. The specialties business includes three major therapeutic areas: Cancer Chemotherapy, Cardiology, and Anti-Infectives. TPL has established itself as a leader in its field by providing affordable medicines to patients across India. In addition to cancer care, TPL is also recognized for its anti-infective products, such as Ciprofloxacin which are widely used in treating bacterial infections. 

Business Verticals

Torrent Pharmaceuticals is a global specialty pharmaceutical and OTC medicines player. The Company has two divisions: Pharmaceuticals and Consumer Healthcare (OTC). 

Torrent's Pharmaceuticals division consists of three major therapeutic areas: Cardiovascular, Central Nervous System (CNS) and Metabolic Diseases. Its products include branded formulations for treating cardiovascular diseases, central nervous system disorders and metabolic diseases. They are available as tablets, capsules, injectables and syrups. 

It also offers active pharmaceutical ingredients (APIs), which other companies use to manufacture their drugs. In addition, Torrent's Pharmaceuticals markets its consumer healthcare products through its direct sales force in India. Torrent has manufacturing facilities across India and exports its products to over 80 countries worldwide.

Milestones

1959 - Shri U. N. Mehta ventured in the pharmaceutical  industry.

1971 - Trinity Laboratories was renamed as Torrent Pharmaceuticals Limited.

1980 - The first manufacturing facility was established in Ahmedabad at Vatva.

1983 - Torrent Pharmaceuticals enters international markets with the first export order to the USSR.

1984
Torrent Laboratories Limited wins Chemexcil Export Award.
Torrent Laboratories Limited received the Udyog Ratna Award.

1985
After demonstrating exceptional export performance, Torrent Laboratories Limited is honoured with the IMC Golden Jubilee Endowment Award.
Torrent Exports Limited wins the Gujarat Government export award.
IDMA awarded Torrent Laboratories Limited the Quality Excellence Award.

1986
Torrent Laboratories Limited wins the Chemexcil Export Award third time in a row.
The IDMA Quality Excellence Award was presented to Torrent Laboratories Limited.
Torrent Exports Limited wins the Gujarat Government export award again.

1987
Torrent Laboratories Limited wins the Chemexcil Export Award for the fourth consecutive year.
The Gujarat government awarded Torrent Exports Limited an export award for the third time.

1988 - Torrent Laboratories Limited wins the Chemexcil Export Award for the fifth consecutive year.

1989
Torrent Laboratories establish their second manufacturing plant.
Chemexcil Trishul Award for Highest Pharma Exports awarded to Torrent Exports Limited.
Torrent Pharmaceuticals Limited wins the IDMA Quality Excellence Award.

1990
Torrent Exports Limited wins the National Export Award.
Torrent Pharmaceuticals Ltd wins the International Friendship's Pride of Asia International award for excellence in pharmaceutical products.

1992 - Torrent Pharmaceuticals Limited wins the IDMA Quality Excellence Award for the second time.

1995 - The Torrent Gujarat Biotech Limited plant gets commissioned.

1999
Torrent Pharmaceuticals Ltd gets revamped. Three new divisions, Prima, Vista, and Psycan, are formed.
Torrent Research Center receives its first patent for a new chemical entity.
Torrent Exports Limited wins the GCCI Export Recognition Award
Torrent Pharma wins the IDMA Gold Trophy.

2000
Torrent Research Center is awarded the OECD Standards of Good Laboratory Practices Certificate by the Dutch Health Ministry.
The Indrad Plant gets the ISO 9001:2000 certification.

2001
In terms of Return on Capital Employed, Torrent Pharma was ranked among the top ten Indian companies (ET - BCG Study Feb - 2001).
Torrent Pharmaceuticals wins the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation.
Torrent Pharma wins the IDMA Quality Excellence Award Gold Trophy for its Formulation facility. It is awarded the Silver Trophy for its API manufacturing facility as well.
Torrent do Brasil Ltda. was founded and incorporated in Brazil.

2002
The AGE (Advanced Glycosylation End-products) molecule is discovered and patented.
Torrent Pharma's Indrad Plant gets ISO 14001:1996 and OHSAS 18001:1999 certifications.
Torrent's R&D Center with ISO/IEC 17025:1999 gets accredited by the National Accreditation Board for Testing and Calibration Laboratories for its facilities (NABL).
Torrent Pharmaceuticals Ltd launches a new marketing division, MIND.
Torrent Research Center develops its own Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System, and Multiparticulate / Matrix Based SR / Modified Release Formulations.

2003
Torrent Pharma Inc. is founded and incorporated in the United States.
Torrent Pharmaceuticals Manufacturing Plant receives GMP certification from the European Union.
Torrent Pharma Philippines Inc. is founded and incorporated.
Torrent Pharma received the Gold Trophy for the IDMA Quality Excellence Award again for its formulation and API manufacturing facilities.

2006
The API and formulation manufacturing facilities in Indrad (Gujarat, India) receive the most coveted US FDA approval.
South African Torrent Pharma and Pharma Dynamics (Pty) Ltd signed a Technical Agreement to supply various products.

2007
Indrad Plant with ISO 9001: 2000 (Quality Management System), ISO 14001:2004 (Environmental Management System), and OHSAS 180001:1999 (Occupational Health and Safety Management System) get certified by ISOQAR, a UKAS accredited body.
Sikkim Plant construction begins.

2008 - The Baddi Plant gets the prestigious GMP certification from the Government of Upper Bavaria in Germany.

2009
Novo Nordisk commissions a dedicated formulation and packaging unit to Torrent Pharmaceuticals Ltd for exclusively manufacturing Insulin.
AstraZeneca signed a license and supply agreement to market its products in the international market.
Baddi Plant gets a five-star rating from the British Safety Council.

2010
Baddi Plant receives the OHSAS Audit 18001:2007 certification. Uganda's regulatory authority approves the Baddi Plant facility.
An advanced facility for Stability Studies gets established at the Indrad Plant.
Torrent Pharmaceuticals Ltd enter the field of gynaecology therapy.
Laboratories Torrent S.A. de C.V Mexico begins its commercial operations.
Dahej manufacturing facility construction begins.

2011
The Sikkim Plant begins operations.
Torrent Research Center creates an indigenous nasal drug delivery system.
Torrent Pharmaceuticals Ltd launches Sparsh, a dedicated division to serve the Dermatology Segment.

2012
The Indrad Plant is bestowed with the Sword of Honor for Occupational Health and Safety by the British Safety Council.
Torrent Research Center discovers the Topical Foams system.

2013 - Torrent Pharma signs a licensing agreement with Reliance Life Sciences for three biosimilars: rituximab, adalimumab, and cetuximab.

2014
Elder Pharma's identified Indian Branded Formulation Business in India and Nepal gets acquired by Torrent Pharmaceuticals. 
Nephro, a dedicated division is established to exclusively serve the Nephrology Segment.
The Dahej Plant of Torrent Pharma initiates their operations.

2015
10th CNBC TV18 India Business Leader Awards 2014 witnesses the victory of Torrent Pharma as the Most Promising Company of the Year.
Torrent acquired Zyg Pharma.

2016
The Dahej Plant gets the USFDA certification.
Torrent Pharmaceuticals acquires API manufacturing unit of Hyderabad-based Glochem Industries Limited.

2017
Torrent Pharmaceuticals acquire Unichem's domestic and Nepal operations along with its Sikkim manufacturing facility.
Business World Magazine names them as one of the top five 'Fastest Growing Companies (Middleweights Category)'.
Executive Chairman, is named as one of India's Most Valuable CEOs in the by Business World Magazine.
Torrent Pharmaceuticals acquires all Novartis' Women Healthcare brands.

2018 - Torrent makes its first overseas purchase by acquiring Bio-Pharm Inc. (BPI), based in the United States along with a US FDA-registered manufacturing facility. 

2019 - Torrent and Glenmark sign a licensing agreement for co-marketing Remogliflozin Etabonate pan-India.

2021
In India, Torrent Pharma launches MSD (a trademark of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgeback's Molnupiravir under the brand name Molnutor®.
Torrent Pharma Signs Voluntary Licensing Agreement with Lilly to produce and distribute Baricitinib for Covid-19 in India.

2022 
Torrent finalizes the acquisition of Dr. Reddy's Laboratories Ltd. four brands: "Styptovit-E," "Finast," "Finast-T," and "Dynapress."
Torrent Pharma signs a licensing agreement with Medicine Patent Pool for the production and marketing of a generic version of Pfizer's Oral COVID-19 Treatment.

Torrent Pharmaceuticals FAQs

What is Share Price of Torrent Pharmaceuticals ?

Torrent Pharmaceuticals share price is ₹1615 As on 07 December, 2022 | 06:13

What is the Market Cap of Torrent Pharmaceuticals ?

The Market Cap of Torrent Pharmaceuticals is ₹54664 Cr As on 07 December, 2022 | 06:13

What is the P/E ratio of Torrent Pharmaceuticals ?

The P/E ratio of Torrent Pharmaceuticals is 68.6 As on 07 December, 2022 | 06:13

What is the PB ratio of Torrent Pharmaceuticals ?

The PB ratio of Torrent Pharmaceuticals is 9.2 As on 07 December, 2022 | 06:13

What were the company's most recent reported sales and net income?

Torrent Pharmaceuticals Ltd recorded a net sales of INR 8508 crores in the year ending March 2022.

What is the future of the company's shares?

Torrent Pharmaceuticals Ltd stock is a good option for long-term investment since the stock prices indicate a strong buying trend.

How to buy shares of Torrent Pharmaceuticals Ltd.?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

Q2FY23